Century Therapeutics, Inc.

NasdaqGS IPSC

Century Therapeutics, Inc. Price to Book Ratio (P/B) on January 14, 2025: 0.41

Century Therapeutics, Inc. Price to Book Ratio (P/B) is 0.41 on January 14, 2025, a -58.77% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Century Therapeutics, Inc. 52-week high Price to Book Ratio (P/B) is 1.61 on April 11, 2024, which is 294.91% above the current Price to Book Ratio (P/B).
Century Therapeutics, Inc. 52-week low Price to Book Ratio (P/B) is 0.41 on January 14, 2025, which is 0.00% below the current Price to Book Ratio (P/B).
Century Therapeutics, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 0.94.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqGS: IPSC

Century Therapeutics, Inc.

CEO	Mr. Brent Pfeiffenberger M.B.A., Pharm.D.
IPO Date	June 18, 2021
Location	United States
Headquarters	3675 Market Street
Employees	152
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

Key trends

Past 5 years